文献速递肝病消化道肿瘤与早癌

COVID-19大流行凸显国家卫生系统改进肝细胞癌筛查与诊断的机会

The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

研究评估COVID-19大流行对退伍军人健康管理局肝硬化患者肝细胞癌筛查与诊断的影响。比较2019年9月1日至2020年2月29日(COVID-19前,N=94,612)与2020年4月1日至2020年9月30日(COVID-19后,N=88,073)的筛查与诊断率及预测因素。结果显示COVID-19后筛查率下降44%,诊断率下降13%;筛查下降与肝病严重程度无关,而诊断下降仅见于终末期肝病模型-钠评分<20或纤维化-4评分<3.25的患者。纤维化-4评分≥3.25和肝细胞癌风险≥1.5%/年强烈预测肝细胞癌诊断,但仅中度预测接受筛查。

要点

  • COVID-19后肝细胞癌筛查率下降44%,诊断率下降13%。
  • 筛查下降与肝病严重程度无关,诊断下降仅见于MELD-Na<20或FIB-4<3.25者。
  • FIB-4≥3.25和HCC风险≥1.5%/年强烈预测诊断,但仅中度预测筛查接受。

核心结论

  • COVID-19大流行后肝细胞癌筛查和诊断率下降,优先对肝细胞癌风险最高的患者进行筛查可能减少诊断延迟。

研究设计与样本

  • 研究评估COVID-19大流行对退伍军人健康管理局肝硬化患者肝细胞癌筛查与诊断的影响,比较COVID-19前(2019年9月1日至2020年2月29日,N=94,612)与COVID-19后(2020年4月1日至2020年9月30日,N=88,073)的筛查与诊断率及预测因素。

主要发现

  • COVID-19后筛查率下降44%,诊断率下降13%。
  • 筛查下降与肝病严重程度无关,诊断下降仅见于MELD-Na评分<20或FIB-4评分<3.25的患者。
  • FIB-4评分≥3.25和HCC风险≥1.5%/年强烈预测HCC诊断,但仅中度预测接受筛查。

临床怎么用

  • 作者认为优先对肝细胞癌风险最高的患者进行筛查可能减少诊断延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We evaluated the coronavirus disease 2019 (COVID-19) pandemic's impact on hepatocellular carcinoma (HCC) screening and diagnosis among patients with cirrhosis in the Veterans Health Administration. METHODS: Rates and predictors of screening and diagnosis were reviewed September 1, 2019-February 29, 2020 ("pre-COVID-19," N = 94,612) and April 1, 2020-September 30, 2020 ("post-COVID-19," N = 88,073). RESULTS: Screening and diagnosis rates declined by 44% and 13%, respectively, after the COVID-19 pandemic. Screening declined irrespective of liver disease severity, but diagnosis declined only in Model for End Stage Liver Disease-Sodium score <20 or Fibrosis-4 score <3.25. Fibrosis-4 score ≥3.25 and HCC risk ≥1.5%/year strongly predicted HCC diagnosis but only moderately predicted receipt of screening. DISCUSSION: Screening and diagnosis rates declined after the COVID-19 pandemic. Prioritizing screening for patients at greatest risk for HCC may reduce delays in diagnosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, et al. The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. Am J Gastroenterol. 2022. PMID: 35029156. doi:10.14309/ajg.0000000000001615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。